TARDBP and amyotrophic lateral sclerosis: Since the implication of TDP‐43 in the pathogenesis of ALS and FTLD, multiple aspects of TDP‐43 proteinopathies, such as TDP‐43 expression levels, altered intracellular distribution, post‐translational modifications, truncation, aggregation, degradation, etc. have been targeted for candidate drug screening (reviewed in [286]), with an aim to ultimately put them to the clinical test for their ability to halt or delay the progression of these debilitating diseases in human patients.